Krystal Biotech Inc

NASDAQ:KRYSUnited States

Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. It is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include VYJUVEK, KB407, KB408, KB707, KB105, KB104, KB104, and KB301. Its commercial product VYJUVEK is a non-invasive, topical, redo sable gene therapy designed to deliver two copies of theCOL7A1 gene when applied directly to DEB wounds. VYJUVEK is designed to treat DEB at the molecular level by providing the patient’s skin cells the template to make normal COL7 protein, thereby addressing the fundamental disease-causing mechanism. KB407 is developed for the treatment of Cystic Fibrosis. KB408 is developed for the treatment of Alpha-1 Antitrypsin Deficiency. KB707 is developed for the treatment of solid tumors. KB105 is developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis.

Contact Information

Headquarters

2100 Wharton St Ste 701PITTSBURGH, PA, United States 15203-1973

Phone

412-586-5830

Fax

302-655-5049

Executives

Chairman of the Board, President, Chief Executive Officer

Krish Krishnan

Founder, Chief Operating Officer, Director, President - Research and Development

Suma Krishnan

Chief Accounting Officer

Kathryn Romano

Lead Independent Director

Daniel Janney

Independent Director

Julian Gangolli